Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Baclofen, a GABA(B) receptor agonist, has shown promise in preclinical models and open-label human studies for reducing alcohol intake and craving.
• Previous research indicates potential efficacy in managing alcohol-related behaviors.

Purpose of the Study:

• To evaluate the efficacy of baclofen in inducing and maintaining abstinence in alcohol-dependent patients.
• To assess baclofen's effect on reducing alcohol craving and consumption in a double-blind, placebo-controlled setting.

Main Methods:

• 39 alcohol-dependent patients were enrolled and randomized to receive either baclofen (30 mg/day) or placebo for 30 days.
• Patients were monitored weekly for alcohol intake, abstinence, craving, and affective disorders.

Main Results:

• The baclofen group showed a higher percentage of total abstinence and more cumulative abstinence days compared to placebo.
• Baclofen significantly reduced obsessive-compulsive craving, alcohol intake, and state anxiety.
• No significant differences in depressive symptoms were observed; baclofen was well-tolerated with no drug craving.

Conclusions:

• Baclofen demonstrated effectiveness in promoting alcohol abstinence and reducing craving and consumption in alcohol-dependent individuals.
• Preliminary findings suggest baclofen as a potentially valuable therapeutic agent for alcohol dependence, warranting further investigation.